La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company has historically focused on the development and testing of Riquent® (abetimus sodium), as a treatment for patients with lupus. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions.
VN:F [1.9.7_1111]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.7_1111]